Chemical Names: 4-androsten-3-one-17beta-ol 17beta-hydroxy-a ndrost-4-en-3-one
Estrogenic Activity: moderate
Progestational Activity: low
Testosterone enanthate is a slow-acting injectable spring of the androgen testosterone.
Coming after deep intramuscular injection, the drug is planned to offer a persistent release of testosterone into the bloodstream for about two to three weeks.
As with all testosterone injectables, testosterone enanthate is extremely preferred by athletes for its efficiency to advertise strong gains in muscle mass and force.
Testosterone enanthate is wide disposable in human an ( veterinary drug marketplaces. Composing and dose change by country and manufacturer, but generally involve fifty-one mg/ml, one hundred mg/ml, two hundred mg/ml, or 250 mg/ml of steroid ) soluble in oil.
Testosterone enanthate is a modified sort of testosterone.
The half-life of testosterone enanthate about 8 days after injection.
Side Effects (Estrogenic):
Testosterone is promptly aromatised in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is liable for this metabolic process of testosterone. Raised estrogen levels could induce side effects specified raised water retention, body fat gain, and gynecomastia.
An anti-estrogen such as Clomid or tamoxifen citrate may represent required to prevent estrogenic side effects.
Side Effects (Androgenic):
Testosterone is the basal male androgen, liable junior upholding secondary male sexual characteristics. Raised rank of testosterone are likely to make androgenic side effects involving oily skin, acne, and body/facial hair growth.
Side Effects (Hepatotoxicity):
Testosterone doesnt have hepatotoxic effects; liver toxicity is unlikely.
Testosterone, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in normal and delayed-release (depot) forms. In September 1995, the FDA approved testosterone transdermal patches (Androderm), and many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA-approved in July 2003; Striant is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation of testosterone (Natesto). A transdermal patch (Intrinsa) for hormone replacement in women is under investigation; the daily dosages used in women are much lower than for products used in males. The FDA refused approval for Intrinsa in 2004 stating that more data regarding safety, especially in relation to cardiovascular and breast health, were required.